See more : SCSK Corporation (9719.T) Income Statement Analysis – Financial Results
Complete financial analysis of Valneva SE (VALN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Valneva SE, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hemlo Explorers Inc. (CNOBF) Income Statement Analysis – Financial Results
- Benesse Holdings, Inc. (9783.T) Income Statement Analysis – Financial Results
- GasLog Ltd. (GLOG-PA) Income Statement Analysis – Financial Results
- Phibro Animal Health Corporation (PAHC) Income Statement Analysis – Financial Results
- Fox-Wizel Ltd. (FXWZF) Income Statement Analysis – Financial Results
Valneva SE (VALN)
About Valneva SE
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 153.71M | 361.30M | 348.09M | 110.32M | 126.20M | 113.04M | 105.29M | 94.06M | 78.36M | 36.92M | 30.45M | 3.43M | 10.26M | 8.40M | 3.10M | 3.42M | 866.00K | 2.33M | 3.01M |
| Cost of Revenue | 100.88M | 324.44M | 187.92M | 54.30M | 49.97M | 43.43M | 45.98M | 43.08M | 46.96M | 17.14M | 16.51M | 11.10M | 6.72M | 6.54M | 5.26M | 2.75M | 1.68M | 726.00K | 475.00K |
| Gross Profit | 52.84M | 36.86M | 160.17M | 56.02M | 76.23M | 69.60M | 59.31M | 50.99M | 31.40M | 19.78M | 13.94M | -7.66M | 3.54M | 1.86M | -2.16M | 673.00K | -817.00K | 1.60M | 2.54M |
| Gross Profit Ratio | 34.37% | 10.20% | 46.01% | 50.78% | 60.40% | 61.58% | 56.33% | 54.20% | 40.07% | 53.57% | 45.78% | -223.38% | 34.50% | 22.11% | -69.80% | 19.69% | -94.34% | 68.83% | 84.22% |
| Research & Development | 59.89M | 104.92M | 173.28M | 84.45M | 37.88M | 12.19M | 23.36M | 24.59M | 25.37M | 22.24M | 21.42M | 12.89M | 12.17M | 13.13M | 9.87M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 47.80M | 34.07M | 47.61M | 38.01M | 27.51M | 36.30M | 15.55M | 14.41M | 14.39M | 14.14M | 14.72M | 4.18M | 262.00K | 3.69M | 3.06M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 48.75M | 23.51M | 23.64M | 7.52M | 14.62M | 11.74M | 17.88M | 16.64M | 9.12M | 2.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 96.55M | 57.58M | 71.25M | 45.52M | 42.13M | 48.04M | 33.42M | 31.05M | 23.52M | 14.14M | 14.72M | 4.18M | 262.00K | 3.69M | 3.06M | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | -21.52M | -12.20M | -22.98M | -18.85M | -3.07M | 19.83M | 6.49M | 37.79M | 2.48M | 7.15M | -91.00K | -798.00K | 8.39M | -636.00K | 3.38M | 3.83M | 3.97M | 1.82M | 3.97M |
| Operating Expenses | 134.92M | 150.31M | 221.56M | 111.13M | 76.95M | 63.34M | 63.27M | 93.43M | 51.36M | 43.53M | 36.05M | 16.26M | 8.65M | 16.81M | 3.38M | 3.83M | 3.97M | 1.82M | 3.97M |
| Cost & Expenses | 235.80M | 474.75M | 409.48M | 165.43M | 126.92M | 106.77M | 109.25M | 136.51M | 98.32M | 60.68M | 52.56M | 16.26M | 15.37M | 16.81M | 8.64M | 6.57M | 5.65M | 2.55M | 4.44M |
| Interest Income | 1.21M | 260.00K | 249.00K | 119.00K | 199.00K | 178.00K | 72.00K | 290.00K | 3.10M | 225.00K | 191.00K | 435.00K | 757.00K | 389.00K | 312.00K | 972.00K | 550.00K | 91.00K | 34.00K |
| Interest Expense | 23.33M | 19.05M | 16.96M | 10.74M | 2.63M | 3.79M | 5.06M | 6.09M | 9.72M | 4.39M | 1.21M | 533.00K | 699.00K | 786.00K | 161.00K | 207.00K | 154.00K | 25.00K | 81.00K |
| Depreciation & Amortization | 17.58M | 21.04M | 14.28M | 9.80M | 8.53M | 6.83M | 11.14M | 11.27M | 11.44M | 12.36M | 9.06M | 4.78M | 3.32M | 2.62M | 1.59M | 1.31M | 1.22M | 328.00K | 1.52M |
| EBITDA | -57.72M | -99.39M | -46.87M | -46.11M | 9.71M | 12.85M | 3.64M | -31.47M | 9.76M | -9.19M | -13.36M | -7.69M | 795.00K | -6.08M | -4.70M | -1.82M | -3.02M | 605.00K | 998.00K |
| EBITDA Ratio | -37.55% | -31.32% | -13.46% | -41.08% | 8.01% | 12.74% | 6.98% | -0.97% | -1.58% | -30.38% | -42.13% | -220.69% | -10.04% | -69.04% | -127.58% | -53.31% | -348.50% | 23.06% | 30.89% |
| Operating Income | -82.09M | -113.44M | -61.39M | -55.11M | 1.50M | 6.26M | -3.95M | -42.57M | -19.93M | -23.82M | -20.86M | -12.83M | -4.45M | -8.42M | -6.30M | -3.15M | -4.79M | -221.00K | -1.43M |
| Operating Income Ratio | -53.40% | -31.40% | -17.64% | -49.95% | 1.19% | 5.54% | -3.76% | -45.26% | -25.44% | -64.50% | -68.50% | -374.03% | -43.37% | -100.26% | -203.33% | -92.28% | -552.54% | -9.49% | -47.49% |
| Total Other Income/Expenses | -16.54M | -31.37M | -8.59M | -10.18M | -59.00K | -2.91M | -8.61M | -6.26M | -13.64M | -2.12M | -2.77M | -56.00K | 1.43M | -397.00K | 3.58M | 765.00K | 396.00K | -25.00K | 34.00K |
| Income Before Tax | -98.63M | -144.82M | -69.98M | -65.30M | -870.00K | 3.35M | -12.56M | -48.83M | -20.39M | -25.94M | -23.63M | -12.89M | -4.39M | -9.45M | -6.14M | -2.39M | -4.39M | -246.00K | -1.40M |
| Income Before Tax Ratio | -64.16% | -40.08% | -20.10% | -59.19% | -0.69% | 2.96% | -11.93% | -51.91% | -26.03% | -70.25% | -77.60% | -375.66% | -42.80% | -112.57% | -198.45% | -69.89% | -506.81% | -10.56% | -46.36% |
| Income Tax Expense | 2.80M | -1.54M | 3.45M | -909.00K | 874.00K | 88.00K | -1.08M | 356.00K | 224.00K | 334.00K | 348.00K | 96.00K | 26.00K | -1.49M | 0.00 | 24.00K | -1.03M | -3.00K | -176.00K |
| Net Income | -101.43M | -143.28M | -73.43M | -64.39M | -1.74M | 3.26M | -11.48M | -49.18M | -20.62M | -26.27M | -24.11M | -14.84M | -4.42M | -7.96M | -6.14M | -2.39M | -3.36M | -243.00K | -1.22M |
| Net Income Ratio | -65.99% | -39.66% | -21.09% | -58.37% | -1.38% | 2.89% | -10.91% | -52.29% | -26.31% | -71.15% | -79.19% | -432.56% | -43.06% | -94.84% | -198.45% | -69.89% | -388.22% | -10.43% | -40.52% |
| EPS | -1.46 | -2.48 | -1.50 | -1.42 | -0.04 | 0.08 | -0.30 | -1.32 | -0.56 | -0.94 | -1.22 | -1.40 | -0.42 | -0.92 | -0.84 | -0.28 | -0.52 | -0.05 | -0.24 |
| EPS Diluted | -1.46 | -2.48 | -1.50 | -1.42 | -0.04 | 0.08 | -0.30 | -1.32 | -0.56 | -0.94 | -1.22 | -1.40 | -0.42 | -0.92 | -0.84 | -0.28 | -0.52 | -0.05 | -0.24 |
| Weighted Avg Shares Out | 69.31M | 57.74M | 48.81M | 45.38M | 45.87M | 40.26M | 38.27M | 37.33M | 36.37M | 27.75M | 19.67M | 10.63M | 10.50M | 8.75M | 7.31M | 8.42M | 6.53M | 5.10M | 5.10M |
| Weighted Avg Shares Out (Dil) | 69.31M | 57.74M | 48.81M | 45.38M | 45.87M | 40.80M | 38.72M | 37.33M | 36.37M | 27.75M | 19.67M | 10.63M | 10.54M | 8.75M | 7.31M | 8.42M | 6.53M | 5.10M | 5.10M |
Valneva: VLA1553 Takes The Lead In The Chikungunya Vaccine Race
Positive Phase 3 data from Bavarian Nordic's chikungunya virus (CHIKV) vaccine candidate, PXVX0317, reinforces bullish view on Valneva's VLA1553 due to its superior clinical profile. Valneva's VLA1553 demonstrated impressive seroresponse rates and durability, with future data releases from Bavarian Nordic's...
Strength Seen in Valneva SE Sponsored ADR (VALN): Can Its 15.8% Jump Turn into More Strength?
Valneva SE Sponsored ADR (VALN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
Saint- Herb lain (France) , May 31 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will attend the Jefferies Healthcare Conference (June 7-9 in New York),...
Valneva (VALN) Stock Down 53% in the Past Year: Here's Why
The European Commission's revised advance purchase agreement jeopardizes Valneva's (VALN) COVID-19 vaccine program.
Valneva SE (VALN) Q1 2023 Earnings Call Transcript
Valneva SE (NASDAQ:VALN ) Q1 2023 Earnings Conference Call May 4, 2023 9:00 AM ET Company Participants Joshua Drumm - VP, IR Thomas Lingelbach - Chairman, President & CEO Peter Buhler - CFO Conference Call Participants Kevin Strang - Jefferies...
Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C.
Saint Herblain (France), March 30, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today it will present on its single-shot chikungunya vaccine candidate, VLA1553, and host a roundtable on Zika vaccines next week at...
Valneva Q4: Resilient Pipeline And Partnership With Pfizer, Reinforcing A Promising Future
Valneva's pipeline and high-stakes clinical catalysts warrant a buy rating, despite the setback in its Lyme disease Phase 3 trial. The CHIKV vaccine candidate is on track for PDUFA in August 2023, and the company plans to launch one or...
Valneva SE (VALN) Q4 2022 Earnings Call Transcript
Valneva SE (NASDAQ:VALN ) Q4 2022 Earnings Conference Call March 23, 2023 10:00 AM ET Company Participants Joshua Drumm - Vice President of Investor Relations Thomas Lingelbach - Chief Executive Officer Peter Buhler - Chief Financial Officer Conference Call Participants...
Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001
Saint - Herblain ( France), March 2 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced additional data from remaining clinical studies and an update on regulatory submissions for its inactivated...
Valneva to Present at the Cowen 43rd Annual Healthcare Conference
Saint- Herb lain (France) , March 1 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at...
Source: https://incomestatements.info
Category: Stock Reports